百诚医药(301096) - 2025 Q2 - 季度业绩预告

Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. 2025 Semi-Annual Performance Forecast Core Performance Forecast Data The company anticipates a substantial year-over-year decline in its 2025 first-half performance, with net profit attributable to shareholders projected to be between 0 and 6 million yuan Performance Forecast Summary | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | Profit: 0 Million Yuan – 6 Million Yuan | Profit: 134.2105 Million Yuan | | | Year-over-Year Decrease: 95.53% - 100.00% | | | Net Profit After Non-Recurring Items | Loss: 9 Million Yuan – 15 Million Yuan | Profit: 123.1989 Million Yuan | | | Year-over-Year Decrease: 107.31% - 112.18% | | Communication with Accounting Firm The company has pre-communicated with its accounting firm regarding the performance forecast, confirming no major discrepancies, though the forecast remains unaudited - The financial data in this performance forecast is unaudited by the accounting firm, but the company has pre-communicated with the accounting firm on related matters, and there are no significant discrepancies between the parties[5] Analysis of Performance Changes The company attributes performance changes to increased Q2 revenue from R&D commercialization and strict cost control, alongside significant government subsidies - In the second quarter of 2025, the company intensified the commercialization of its independent R&D achievements, leading to a sequential increase in revenue and achieving a turnaround from loss to profit in the first half compared to 2024 through strict cost and expense control[6] - During the reporting period, the estimated impact of non-recurring gains and losses on net profit is approximately 15 million yuan, primarily from government subsidies recognized in current profit or loss[6] Risk Warning and Other Explanations The company states this performance forecast is preliminary, with final data in the 2025 semi-annual report, advising investors to exercise caution - This performance forecast represents preliminary data from the company's finance department; the final financial data will be subject to the company's 2025 semi-annual report, and investors are advised to be aware of investment risks[7]